The case for & against
Bull & Bear analysis
Bullish
ADC Therapeutics (NYSE: ADCT) is a clinical-stage immunotherapy company dedicated to developing targeted therapies utilizing antibody-drug conjugates (ADCs) for patients with hematologic malignancies, primarily focusing on diffuse large B-cell lymphoma (DLBCL). The company's flagship product, Zynlanta, is positioned within a competitive oncology landscape and is expected to capture significant growth opportunities following critical clinical trial outcomes, particularly the upcoming results from the Lotus 5 and Lotus 7 trials, which could dramatically influence its market positioning and revenue potential.
Bull says
- ↑Q1 net product revenues rose 15% YoY to $20M, indicating stable demand for Zynlanta.
- ↑$231M cash runway supports trials and operations through 2028, reducing dilution risk.
- ↑Potential peak annual revenues of $600M–$1B upon positive Lotus 5/7 trial outcomes.
- ↑Upcoming Lotus 5 top-line data by June acts as a key catalyst for label expansion.
- ↑Strong 13F ownership and momentum factors suggest institutional investor confidence.
- ↑High leverage exposure paired with robust QS score underscores operational strength.
Bear says
- ↓Q1 net loss narrowed to $33M vs $38.6M YoY but still indicates negative profitability.
- ↓Operating expenses remain high at $46.1M despite a 13% reduction, sustaining cash burn.
- ↓Clinical outcomes from Lotus 5/7 trials are uncertain and essential for growth.
- ↓Competitive pressure from bispecific therapies by Roche and others could limit uptake.
- ↓Cash runway into 2028 may shorten if trials delay or costs rise, posing liquidity risk.
- ↓Negative earnings yield and low profitability factor highlight return-generation struggles.
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-18-2026bullish
Transcript signals
Bull points
- Initial data from the safety lead-in portion of Bluetooth 5, our phase 3 confirmatory study of Zinlanta in combination with Rituximab in patients with second-line plus DLDCL showed an overall response rate of 80% and a complete response rate of 50% with no new safety signals.
- The combination has shown a manageable safety profile, and no new safety signal was observed.
- In the study, we have seen 93.3 overall response rates and an 86.7 complete response rates. Complete responses were observed regardless of prior therapy of the six patients previously treated with SCAR-T and undergoing response assistance, five achieved a CR.
Bear points
- incurred $13.1 million in restructuring and impairment cost in the second quarter of 2025, which consisted of $6.7 million in employee severance and related benefit costs, and $6.4 million in non-cash and permanent assets in connection with the close down of the UK facility.
- On a GAAP basis, we reported a net loss of $56.6 million for the second quarter of 2025, or 50 cents per basic and diluted share as compared to a net loss of $36.5 million or 38 cents per basic and diluted share for the same period in 2024. The increase in net loss for the quarter is primarily attributable to one-time restructuring and impairment cost and higher R&D expenses.
- As research and development efforts and related programs are closed out, we plan to shut down our UK facility reducing our global workforce across functions by approximately 30%.
Read full transcript analysis ›